Evidence map›Paper›PMID 35851807›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Catheter ablation for patients with atrial fibrillation and heart failure with reduced and preserved ejection fraction: insights from the KiCS-AF multicentre cohort study.

Yasuyuki Shiraishi, Shun Kohsaka, Nobuhiro Ikemura, Takehiro Kimura, Yoshinori Katsumata, Kojiro Tanimoto, Masahiro Suzuki, Ikuko Ueda, Keiichi Fukuda, Seiji Takatsuki

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Sex differences in atrial fibrillation ablation outcomes in patients with heart failure.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024
    Article
  7. Article
  8. Article
  9. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  10. Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  11. The increasing importance of the ablation therapy in patients with atrial fibrillation and heart failure with preserved ejection fraction.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  12. Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  13. Catheter ablation improved ejection fraction in persistent AF patients: a DECAAF-II sub analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yasuyuki ShiraishiDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-8788-1186
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0003-3779-2972
Nobuhiro IkemuraDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Takehiro KimuraDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Yoshinori KatsumataDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-5576-5789
Kojiro TanimotoDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Masahiro SuzukiDepartment of Cardiology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Ikuko UedaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Seiji TakatsukiDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPNational Hospital Organization · JPTokyo Medical Center · JP

Funding

Scientific Research from the Japan Society for the Promotion of Science 20H03915, 16H05215, 16KK0186
6 · The paper itself

Abstract

aimsThe usefulness of catheter ablation (CA) for atrial fibrillation (AF) across a broad spectrum of heart failure (HF) patients remains to be established. We assessed the association of CA with both health-related quality of life (QoL) and cardiovascular events among HF patients with reduced and preserved left ventricular ejection fraction (LVEF) in an 'all-comer' outpatient-based AF registry. METHODS AND

resultsOf 3303 patients with AF consecutively enrolled in a retrospective multicentre registry that mandated the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire at registration and 1-year follow-up, we extracted data from 530 patients complicating clinical HF. The association between CA and both 1-year change in AFEQT Overall Summary (AFEQT-OS) scores and 2-year composite clinical outcomes (including all-cause death, stroke, and HF hospitalization) was assessed by multivariable analyses. The median duration of AF was 108 days (52-218 days), and 83.4% had LVEF >35%. Overall, 75 patients (14.2%) underwent CA for AF within 1-year after registration. At 1-year follow-up, 67.2% in the ablation group showed clinically meaningful improvements of ≥ 5 points in AFEQT-OS score than 47.8% in the non-ablation group {adjusted odds ratio, 2.03 [95% confidence interval (CI): 1.13-3.64], P = 0.017}. Furthermore, the composite endpoint of all-cause death, stroke, and HF hospitalization occurred less frequently in the ablation group than the non-ablation group [adjusted hazard ratio, 0.27 (95% CI: 0.09-0.86), P = 0.027].

conclusionAmong AF-HF patients, CA was associated with improved QoL and lower risk of cardiovascular events against drug therapy alone, even for patients with mildly reduced and preserved LVEF.

Indexed as

Atrial FibrillationCatheter AblationHeart FailureStrokeCohort StudiesHumansQuality of LifeStroke VolumeTreatment OutcomeVentricular Function, LeftAtrial fibrillationCatheter ablationHeart failureHeart failure hospitalizationQuality of life

Identifiers

PMID35851807
PMCPMC10103568
OpenAlexW4285796580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.